<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Aurion Biotech 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=46405></link><description><![CDATA[Aurion Biotech 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 29 Apr 2026 11:07:55 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/09/12_31017998_20240925144113_5295150514.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea]]></title><link>https://www.newswire.co.kr/newsRead.php?no=997422</link><description><![CDATA[SEATTLE & CAMBRIDGE, Mass. & TOKYO--(Business Wire/Korea Newswire)--Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel) in Japan, for the treatment of bullous keratopathy of the cornea. The Company believes this is the first approved cell therapy for the treatment of ...]]></description><pubDate>Wed, 25 Sep 2024 14:10:00 +0900</pubDate></item><item><title><![CDATA[오리온 바이오텍, 일본에서 수포성 각막증 치료제 ‘Vyznova®’ 출시]]></title><link>https://www.newswire.co.kr/newsRead.php?no=997423</link><description><![CDATA[시애틀/케임브리지, 매사추세츠/도쿄--(Business Wire/뉴스와이어)--삶을 변화시키는 재생 치료제로 수백만 환우의 시력을 회복시키는 사명을 가진 오리온 바이오테크(Aurion Biotech) 가 수포성 각막증(bullous keratopathy of the cornea) 치료제인 ‘비즈노바(Vyznova®)’(일반명: 넬테펜도셀(neltependocel))를 일본에서 상업적으로 출시했다고 24일(현지 시간) 발표했다. 회사는 이 치료제가 각막 내피 질환 치료를 위해 승인된 최초의 세...]]></description><pubDate>Wed, 25 Sep 2024 14:10:00 +0900</pubDate></item></channel></rss>